NCT00755833View on ClinicalTrials.gov

Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

CompletedOBSERVATIONAL
Enrollment

270

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 50

Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.

Trial Locations (1)

SI-1000

Novo Nordisk Investigational Site, Ljubljana

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00755833 - Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months | Biotech Hunter | Biotech Hunter